Morgan Stanley’s Vyant Bio, Inc. Common Stock VYNT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-9
| Closed | -$5 | – | 7797 |
|
|
2023
Q1 | $5 | Sell |
9
-324
| -97% | -$258 | ﹤0.01% | 7685 |
|
|
2022
Q4 | $234 | Sell |
333
-3,677
| -92% | -$5.98K | ﹤0.01% | 7629 |
|
|
2022
Q3 | $11K | Hold |
4,010
| – | – | ﹤0.01% | 7053 |
|
|
2022
Q2 | $18K | Sell |
4,010
-4
| -0.1% | -$18 | ﹤0.01% | 7037 |
|
|
2022
Q1 | $29K | Sell |
4,014
-3,596
| -47% | -$20.9K | ﹤0.01% | 6983 |
|
|
2021
Q4 | $51K | Hold |
7,610
| – | – | ﹤0.01% | 6803 |
|
|
2021
Q3 | $89K | Hold |
7,610
| – | – | ﹤0.01% | 6439 |
|
|
2021
Q2 | $142K | Buy |
7,610
+7,557
| +14,258% | +$141K | ﹤0.01% | 6184 |
|
|
2021
Q1 | $1K | Buy |
53
+46
| +657% | +$1.17K | ﹤0.01% | 7416 |
|
|
2020
Q4 | $0 | Hold |
7
| – | – | ﹤0.01% | 7167 |
|
|
2020
Q3 | $0 | Buy |
+7
| New | +$132 | ﹤0.01% | 6881 |
|
|
2020
Q1 | – | Sell |
-3
| Closed | – | – | 6785 |
|
|
2019
Q4 | $0 | Hold |
3
| – | – | ﹤0.01% | 6834 |
|
|
2019
Q3 | $0 | Sell |
3
-1
| -25% | -$19 | ﹤0.01% | 6827 |
|
|
2019
Q2 | $0 | Sell |
4
-80
| -95% | -$2.5K | ﹤0.01% | 6811 |
|
|
2019
Q1 | $3K | Sell |
84
-8
| -9% | -$329 | ﹤0.01% | 6420 |
|
|
2018
Q4 | $3K | Sell |
92
-32
| -26% | -$2.7K | ﹤0.01% | 6388 |
|
|
2018
Q3 | $20K | Sell |
124
-3
| -2% | -$444 | ﹤0.01% | 6142 |
|
|
2018
Q2 | $17K | Buy |
127
+19
| +18% | +$2.87K | ﹤0.01% | 6188 |
|
|
2018
Q1 | $27K | Hold |
108
| – | – | ﹤0.01% | 6067 |
|
|
2017
Q4 | $30K | Sell |
108
-12
| -10% | -$4.58K | ﹤0.01% | 5975 |
|
|
2017
Q3 | $49K | Sell |
120
-6
| -5% | -$3.13K | ﹤0.01% | 5787 |
|
|
2017
Q2 | $74K | Sell |
126
-7
| -5% | -$4.09K | ﹤0.01% | 5744 |
|
|
2017
Q1 | $82K | Buy |
133
+14
| +12% | +$4.98K | ﹤0.01% | 5673 |
|
|
2016
Q4 | $24K | Sell |
119
-21
| -15% | -$4.77K | ﹤0.01% | 5959 |
|
|
2016
Q3 | $37K | Buy |
140
+3
| +2% | +$919 | ﹤0.01% | 5704 |
|
|
2016
Q2 | $40K | Sell |
137
-12
| -8% | -$4.22K | ﹤0.01% | 5600 |
|
|
2016
Q1 | $63K | Buy |
149
+13
| +10% | +$4.86K | ﹤0.01% | 5516 |
|
|
2015
Q4 | $67K | Sell |
136
-6
| -4% | -$4.33K | ﹤0.01% | 5604 |
|
|
2015
Q3 | $167K | Sell |
142
-8
| -5% | -$12.2K | ﹤0.01% | 5174 |
|
|
2015
Q2 | $266K | Buy |
150
+111
| +285% | +$173K | ﹤0.01% | 5108 |
|
|
2015
Q1 | $46K | Buy |
39
+22
| +129% | +$26.1K | ﹤0.01% | 5832 |
|
|
2014
Q4 | $17K | Sell |
17
-23
| -58% | -$23K | ﹤0.01% | 6097 |
|
|
2014
Q3 | $54K | Sell |
40
-81
| -67% | -$116K | ﹤0.01% | 5714 |
|
|
2014
Q2 | $205K | Buy |
121
+30
| +33% | +$57.1K | ﹤0.01% | 5145 |
|
|
2014
Q1 | $206K | Buy |
91
+48
| +112% | +$123K | ﹤0.01% | 5106 |
|
|
2013
Q4 | $88K | Sell |
43
-66
| -61% | -$143K | ﹤0.01% | 5392 |
|
|
2013
Q3 | $333K | Buy |
+109
| New | +$187K | ﹤0.01% | 4599 |
|
Other funds holding VYNT
Morgan Stanley's VYNT Position: Q2 2023 in Review
Morgan Stanley sold out of Vyant Bio, Inc. Common Stock (VYNT) in Q2 2023, closing a stake of 9 shares — an estimated $5 sold.
Morgan Stanley first reported a position in VYNT in Q3 2013 and held it in 37 quarters. The position peaked at $333K in Q3 2013. 1 fund tracked by Wall St. Rank holds VYNT as of Q2 2023.
- Morgan Stanley reported no remaining Vyant Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Morgan Stanley sold 9 Vyant Bio, Inc. Common Stock shares in Q2 2023, an estimated $5.
- Morgan Stanley first reported a position in Vyant Bio, Inc. Common Stock in Q3 2013 and held it in 37 quarters.
- Morgan Stanley's Vyant Bio, Inc. Common Stock position peaked at $333K in Q3 2013.
- 1 fund tracked by Wall St. Rank held Vyant Bio, Inc. Common Stock as of Q2 2023.
Based on Morgan Stanley's 13F filing for Q2 2023, filed 14 Aug 2023.